PhDs and postdocs - the career development conference in #Philly - one of my favorite cities- you MUST register for! #PhillyStempeers2022 29th Oct, 22 @ChildrensPhila Brought to you by @Stempeer15 the best peer-mentoring group I know! Registrations open: https://t.co/sO5KuIl5vU
We are climbing a ladder of #SARSCoV2 increased infectiousness with booster shots not working as well or as long, with the illusion that the pandemic is over. It's not and there's much we can and should do to get ahead of it
https://t.co/SoWDo6ownt
Responding To Tough Markets: Restructurings In Biotech
Observations on the flurry of #biotech restructurings, the different types of these announcements, and how to successfully navigate them
Which will be the next Jazz, Arena, Illumina, or Madrigal?
https://t.co/md3C2ePyW2
"SPAC downpour continues" - @SamTruex reflects in a new blog post on some of the recent bio SPAC updates and how the market is evolving. #SPAC
https://t.co/kTJd867uNb
How did multicellularity arise in the living world?
Check out the organisms that lie at the edge of the unicellular and multicellular worlds that might hold the answer.
Read here: https://t.co/lyYK7tmXg2
Work by: @AnanyaDash17, @SumbulJawedKhan, @_amritanand, Aryaa Apotikar
Another fantastic analysis on the relationship between the growing number of biotech IPOs and number of “core” positions biotech buy siders have.
Especially for small biotechs seeking to grow, they need:
A compelling story
Robust data that's transformative to the patients.
Biotech’s Relevancy Challenge In An Expanding Universe
The pace of new names to invest in (supply of opportunities from IPOs) has increased faster than the number of potential “big” holders (demand for new core positions in public fund portfolios)
https://t.co/hoxofSGa9E
Biotech’s Relevancy Challenge In An Expanding Universe
The pace of new names to invest in (supply of opportunities from IPOs) has increased faster than the number of potential “big” holders (demand for new core positions in public fund portfolios)
https://t.co/hoxofSGa9E
BREAKING: For decades, scientists struggled to find a medicine that could treat one of the most common cancer mutations. Amgen has won approval from U.S. health regulators for the first drug targeting the KRAS mutation, @joewalkerWSJ reports. https://t.co/QdmdA0uSdJ
. @ChelseaClinton joins the “First Opinion Podcast” this week to discuss her work in public health, starting with the dangers of fracking to maternal and cardiovascular health.
Listen here: https://t.co/ag4iZkNvtp
#podcast
Americans spent $15B during COVID on retail coffee.
We spent over $8B on whiskey and tequila.
As a country, we spent way less than that on COVID vaccines.
In addition to saving countless lives, vaccines have been incredibly good value to society...